162 related articles for article (PubMed ID: 12056551)
21. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
Grantham JA; Schirger JA; Wennberg PW; Sandberg S; Heublein DM; Subkowski T; Burnett JC
Circulation; 2000 Apr; 101(16):1976-81. PubMed ID: 10779465
[TBL] [Abstract][Full Text] [Related]
22. Endothelin-converting enzymes.
Opgenorth TJ; Wu-Wong JR; Shiosaki K
FASEB J; 1992 Jun; 6(9):2653-9. PubMed ID: 1612289
[TBL] [Abstract][Full Text] [Related]
23. Molecular pharmacology of endothelin converting enzymes.
Turner AJ; Murphy LJ
Biochem Pharmacol; 1996 Jan; 51(2):91-102. PubMed ID: 8615890
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme.
Umekawa K; Hasegawa H; Tsutsumi Y; Sato K; Matsumura Y; Ohashi N
Jpn J Pharmacol; 2000 Sep; 84(1):7-15. PubMed ID: 11043447
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and degradation of endothelin-1.
D'Orléans-Juste P; Plante M; Honoré JC; Carrier E; Labonté J
Can J Physiol Pharmacol; 2003 Jun; 81(6):503-10. PubMed ID: 12839262
[TBL] [Abstract][Full Text] [Related]
26. Novel selective quinazoline inhibitors of endothelin converting enzyme-1.
Ahn K; Sisneros AM; Herman SB; Pan SM; Hupe D; Lee C; Nikam S; Cheng XM; Doherty AM; Schroeder RL; Haleen SJ; Kaw S; Emoto N; Yanagisawa M
Biochem Biophys Res Commun; 1998 Feb; 243(1):184-90. PubMed ID: 9473502
[TBL] [Abstract][Full Text] [Related]
27. Endothelin-converting enzyme inhibitors: current status and perspectives.
Löffler BM
J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S79-82. PubMed ID: 10976788
[TBL] [Abstract][Full Text] [Related]
28. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
Roques BP
Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
[TBL] [Abstract][Full Text] [Related]
29. In-silico characterization of ECE-1 inhibitors.
Ajay Babu P; Colluru VT; Anaparthy N
Comput Biol Med; 2012 Apr; 42(4):446-57. PubMed ID: 22245098
[TBL] [Abstract][Full Text] [Related]
30. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines.
Usmani BA; Harden B; Maitland NJ; Turner AJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():314S-317S. PubMed ID: 12193112
[TBL] [Abstract][Full Text] [Related]
32. Effects of dual endothelin-converting enzyme/neutral endopeptidase inhibitors, CGS 26303 and CGS 26393, on lipopolysaccharide or interleukin-1 beta-stimulated release of endothelin from guinea pig tracheal epithelial cells.
Pelletier S; Battistini B; Jeng AY; Sirois P
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S10-2. PubMed ID: 9595386
[TBL] [Abstract][Full Text] [Related]
33. Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.
Berger Y; Dehmlow H; Blum-Kaelin D; Kitas EA; Löffler BM; Aebi JD; Juillerat-Jeanneret L
J Med Chem; 2005 Jan; 48(2):483-98. PubMed ID: 15658862
[TBL] [Abstract][Full Text] [Related]
34. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX.
Turner AJ; Tanzawa K
FASEB J; 1997 Apr; 11(5):355-64. PubMed ID: 9141502
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme.
Nelissen J; Lemkens P; Sann H; Bindl M; Bassissi F; Jasserand D; De Mey JG; Janssen BJ
Life Sci; 2012 Oct; 91(13-14):587-92. PubMed ID: 22365954
[TBL] [Abstract][Full Text] [Related]
36. Effect of endothelin-converting enzyme inhibitors on big endothelin-1 induced contraction in isolated rat basilar artery.
Zimmermann M; Jung CS; Vatter H; Raabe A; Seifert V
Acta Neurochir (Wien); 2002 Nov; 144(11):1213-9. PubMed ID: 12434178
[TBL] [Abstract][Full Text] [Related]
37. Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation.
Brands M; Ergüden JK; Hashimoto K; Heimbach D; Krahn T; Schröder C; Siegel S; Stasch JP; Tsujishita H; Weigand S; Yoshida NH
ChemMedChem; 2006 Jan; 1(1):96-105. PubMed ID: 16892341
[TBL] [Abstract][Full Text] [Related]
38. The endothelin system and endothelin-converting enzyme in the brain: molecular and cellular studies.
Barnes K; Turner AJ
Neurochem Res; 1997 Aug; 22(8):1033-40. PubMed ID: 9239759
[TBL] [Abstract][Full Text] [Related]
39. A three-dimensional model of endothelin-converting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP).
Bur D; Dale GE; Oefner C
Protein Eng; 2001 May; 14(5):337-41. PubMed ID: 11438756
[TBL] [Abstract][Full Text] [Related]
40. Modulation of endothelin production and metabolism in guinea-pig tracheal epithelial cells by peptidase inhibitors.
Yang Q; Battistini B; D'Orléans-Juste P; Jeng AY; Sirois P
Am J Respir Crit Care Med; 1997 Jun; 155(6):1884-9. PubMed ID: 9196090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
